Design and rationale of the WOEST trial: What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST)

American Heart Journal

Volumn 158, Issue 5, 2009, Pages 713-718

  Dewilde, Willem ^a   Berg, Jurriën Ten ^a  

^a ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; DRUG INDICATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; HUMANS; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 70350225584     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.09.001     Document Type: Article

References (30)

1. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation. 114 (2006) e84-e231
2. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 27 (2006) 1979-2030
3. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) 156-175
4. Karjalainen P.P., Porela P., Ylitalo A., et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J 28 (2007) 726-732
5. Orford J.L., Fasseas P., Melby S., et al. Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Heart J 147 (2004) 463-467
6. Leon M.B., Baim D.S., Popma J.J., et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 339 (1998) 1665-1671
7. Rubboli A., Milandri M., Castelvetri, et al. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology 104 (2005) 101-106 [Epub 2005 Jul 12]
8. ACTIVE Writing Group on behalf of the ACTIVE Investigators, Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 367 (2006) 1903-1912
9. Lip G.Y. Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention. BMJ a840 (2008) 337
10. Ruiz-Nodar J.M., Marín F., Hurtado J.A., et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 51 (2008) 818-825
11. Rubboli A., Halperin J.L., Airaksinen K.E., et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 40 (2008) 428-436 [Review]
12. Rubboli A., and Halperin J.L. Pro: "antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions". Thromb Haemost 100 (2008) 752-753
13. Roldán V., and Marín F. Contra: "antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions". Not for everybody. Thromb Haemost. 100 (2008) 754-755
14. Dewilde W., and Ten Berg J.M. the antithrombotic dilemma future. Cardiology 3 (2007) 511-513
15. Buresly K., Eisenberg M.J., Zhang X., et al. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 165 (2005) 784-789
16. Mattichak S.J., Reed P.S., Gallagher M.J., et al. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol 18 (2005) 163-166
17. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S., Mehta S.R., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 354 (2006) 1464-1476
18. Khurram Z., Chou E., Minutello R., et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol 18 (2006) 162-164
19. Porter A., Konstantino Y., Iakobishvili Z., et al. Short-term triple therapy with aspirin, warfarin, and a thienopyridine among patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 68 (2006) 56-61
20. Gilard M., Arnaud B., Cornily J.C., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51 (2008) 256-260
21. Ho P.M., Maddox T.M., Wang L., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301 (2009) 937-944
22. Freedman J.E., and Hylek E.M. Clopidogrel, genetics, and drug responsiveness. N Engl J Med 360 (2009) 411-413
23. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362
24. Simon T., Verstuyft C., Mary-Krause M., et al., for the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360 (2009) 363-375
25. ten Berg J.M., Hutten B.A., Kelder J.C., et al. Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications. Circulation 103 (2001) 2042-2047
26. Silber S., Albertsson P., Avilés F.F., et al., for the Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 26 (2005) 804-847
27. Patel M.R., Dehmer G.J., Hirshfeld J.W., et al. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 appropriateness criteria for coronary revascularization: a report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Circulation. 119 (2009) 1330-1352
28. Chesebro J.H., Knatterud G., Roberts R., et al. Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76 (1987) 142-154
29. The Gusto Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682
30. Cutlip D.E., Windecker S., Mehran R., et al., for the Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351